A Clinical Study Based on FAPI-PET/CT Technology to Predict Pathological Complete Response After Neoadjuvant Chemoradiotherapy for MSS Rectal Cancer

NCT06608537 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

52

Enrollment

OTHER

Sponsor class

Conditions

Rectal Cancer

Interventions

DRUG: neoadjuvant SCRT followed by Sintilimab plus CAPOX

Sponsor

Sun Yat-sen University